An Access Path for Digital Therapeutics

While there has been substantial investment in and focus on the digital health sector, patient access to digital therapeutics (DTx) remains hindered by numerous obstacles, such as regulatory and reimbursement complexities, which ultimately slow progress for improving access. While reimbursement barriers exist for digital therapeutics, ongoing legislative efforts, development of private payer frameworks, and programs such as the Public Health Informatics and Technology Act are shaping a more supportive environment for DTx.

In the Med Ad News article, "Forging an Access Pathway for Digital Therapeutics," Brigit Kyei-Baffour discusses the effort to simplify clinician prescription processes and enhance patient access. She also describes innovative approaches that explore new payment and evaluation models that drive innovation in healthcare delivery.

To read the full article, visit Med Ad News' blog, PharmaLive.com.

Learn More
Avalere works closely with manufacturers and payers to evaluate, develop, and refine patient support programs that are finely attuned to the current policy and market landscape. We also collaborate with digital therapeutics and digital health stakeholders to maximize patient access and affordability. To learn more about how Avalere can assist you, connect with us.